Nasdaq:KPRX
KIORA PHARMACEUTICALS INC
A clinical-stage biotech firm developing novel therapies for oncology and immunology with a diversified product pipeline and strong cash flow generation in 2024.
Key Metrics
Investment Thesis
Bull Case
Investors may buy Kiora Pharmaceuticals due to its successful pivot to profitability in 2024, evidenced by positive net income and strong operating cash flow of $8.6M. The company's proprietary platform offers significant upside potential if future clinical trials succeed, potentially unlocking substantial value upon regulatory approval. With a healthy cash position of $3.8M and substantial paid-in capital, the firm is well-positioned to fund its pipeline through commercial milestones.
Bear Case
Despite 2024 profits, the company's massive retained earnings deficit of $-143.4M suggests long-term historical losses that may require continued external funding or dilution. High operating expenses of $11.5M and significant investing outflows of $-22.7M indicate ongoing pressure to generate sustainable revenue before cash reserves deplete. Clinical-stage biotech investments carry binary risks where a single failed trial could wipe out shareholder value despite current financial metrics.
About KIORA PHARMACEUTICALS INC
Kiora Pharmaceuticals is a clinical-stage biotechnology company focused on discovering and developing novel medicines for serious unmet needs, primarily operating within the oncology and immunology markets. The company leverages its proprietary platform technologies to advance multiple programs through preclinical and clinical development stages. Revenue is currently driven by commercialization of existing assets while significant R&D expenditures support future pipeline expansion.
Analysis
Management Discussion
Kiora Pharmaceuticals demonstrated a significant financial turnaround in 2024, shifting from net losses of $-13.6M and $-12.5M in the prior two years to a net profit of $3.6M. This improvement is reflected in operating cash flow of $8.6M and gross profits reaching $16.0M, indicating effective cost management and potential commercial success. However, the company still maintains a retained earnings deficit of $-143.4M, highlighting that current profitability has not yet offset historical burn rates.
Industry Overview
The pharmaceutical and biotechnology industry is highly competitive, characterized by long development cycles, high regulatory barriers, and substantial R&D requirements. Companies in this sector often operate with thin margins until products gain market approval, relying heavily on intellectual property protection. Success depends on rapidly advancing clinical pipelines to capture market share against large incumbent pharma companies.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $16.0M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $16.0M |
| Operating Expenses | $12.3M | $12.6M | $11.5M |
| Operating Income | $-12.3M | $-12.6M | $4.5M |
| R&D | $3.4M | $4.0M | $7.8M |
| G&A | $8.3M | $4.7M | $5.5M |
| Stock-Based Comp | $462.4K | $754.9K | $656.6K |
| D&A | $41.6K | $51.8K | $19.2K |
| Depreciation | $16.6K | $30.0K | $5.0K |
| Amortization | $25.0K | $25.0K | $15.0K |
| Other OpEx | $582.6K | $3.9M | $-1.9M |
| Non-Operating Income | $-1.4M | $163.3K | $1.1M |
| Interest Expense | $8.6K | $11.1K | — |
| Interest Income | $56.9K | $174.0K | $1.3M |
| Pre-Tax Income | $-13.7M | $-12.4M | $5.7M |
| Income Tax | $-113.0K | $90.3K | $2.1M |
| Continuing Ops | $-13.6M | $-12.5M | $3.6M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-13.6M | $-12.5M | $3.6M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-13.6M | $-12.5M | $3.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $7.7M | $4.7M | $29.7M |
| Cash & Equivalents | $6.0M | $2.5M | $3.8M |
| Marketable Securities | — | — | $23.0M |
| Accounts Receivable | — | — | $601.2K |
| Prepaid Expenses | $343.1K | $233.4K | $2.0M |
| Other Current Assets | $1.4M | $2.0M | $270.2K |
| Long-Term Assets | $11.0M | $9.0M | $6.8M |
| PP&E (Net) | $55.2K | $8.1K | $5.2K |
| Intangibles | $10.7M | $8.8M | $6.7M |
| Goodwill | $0 | — | — |
| Operating Leases | $117.0K | $106.9K | $57.2K |
| Other LT Assets | $82.3K | $45.0K | $29.0K |
| Total Assets | $18.7M | $13.7M | $36.5M |
| Current Liabilities | $3.3M | $1.6M | $6.0M |
| Accounts Payable | $1.0M | $206.3K | $415.6K |
| Current Leases | $105.8K | $47.1K | $23.4K |
| Taxes Payable | — | — | $2.3M |
| Other Current Liab | $322.4K | $0 | $-1.3M |
| Long-Term Liabilities | $4.0M | $6.0M | $4.7M |
| LT Operating Leases | $0 | $59.8K | $33.8K |
| Other LT Liab | $4.0M | $5.9M | $4.7M |
| Total Liabilities | $7.3M | $7.6M | $10.7M |
| Shareholders' Equity | $11.4M | $6.1M | $25.8M |
| Paid-In Capital | $146.0M | $153.2M | $169.2M |
| Retained Earnings | $-134.5M | $-147.0M | $-143.4M |
| AOCI | $-182.7K | $-182.8K | $-282.2K |
| Total L&E | $18.7M | $13.7M | $36.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-13.6M | $-12.5M | $3.6M |
| Non-Cash Adjustments | $1.2M | $3.7M | $728.6K |
| Working Capital Changes | $1.9M | $-712.3K | $4.2M |
| Cash from Operations | $-10.4M | $-9.6M | $8.6M |
| Capital Expenditures | $0 | — | $6.3K |
| Cash from Investing | $6.4K | $0 | $-22.7M |
| Cash from Financing | $8.6M | $6.0M | $15.5M |
| FX Effect | $-85.0K | $36.0K | $-57.2K |
| Net Change in Cash | $-1.9M | $-3.6M | $1.3M |
| Beginning Cash | $7.9M | $6.0M | $2.5M |
| Ending Cash | $6.0M | $2.5M | $3.8M |
Frequently Asked Questions
How does KIORA PHARMACEUTICALS INC make money?
Oncology and Immunology: The company's core revenue stream involves the discovery and development of proprietary medicines targeting cancer and immune-related diseases. Commercial Operations: Revenue is generated through the sale or licensing of approved products, with 2024 revenue totaling $16.0M. R&D and Platform Technologies: Significant investments in research and development ($7.8M) and other operating expenses support the advancement of its drug discovery platform.
What are the main risks for KPRX?
Clinical Development Uncertainty: As a clinical-stage company, the success of future revenue depends on the successful completion of costly and time-consuming clinical trials. Regulatory Approval Risks: Obtaining FDA or other regulatory approvals for new therapies is uncertain and can be delayed by scientific or administrative hurdles. High Burn Rate Potential: Despite 2024 profitability, the company still incurs substantial operating expenses ($11.5M) and R&D costs ($7.8M) that could impact cash reserves if sales do not scale rapidly.
What is KPRX's competitive advantage?
Proprietary Drug Discovery Platform: Kiora utilizes unique technology to identify novel targets for treating serious conditions, potentially offering first-in-class or best-in-class therapies. Strong Financial Turnaround: The company successfully transitioned from net losses in 2022 and 2023 to a positive net profit of $3.6M in 2024, demonstrating improved operational efficiency. Robust Balance Sheet: With $3.8M in cash and equivalents and $169.2M in paid-in capital, the firm maintains financial flexibility to fund its pipeline without immediate dilution.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.